DXR

DAXOR CORP - 10-K Summary (Fiscal Year Ended Dec 31, 2004)

Business Context and Reporting Period

Daxor Corporation is a medical device manufacturer focused on the BVA-100(TM) Blood Volume Analyzer and associated Volumex(TM) diagnostic kits. The company also operates biotech services through its wholly-owned subsidiary, Scientific Medical Systems (Idant), providing long-term cryobanking for blood and semen. The reporting period covers the fiscal year ended December 31, 2004. The company is headquartered in New York, NY, with manufacturing facilities in Oak Ridge, TN.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $1,830,381. Net cash provided by investing activities was $1,680,474, driven largely by proceeds from short sales and loans from brokers. Net cash provided by financing activities was $151,662.

Material Changes vs. Prior Period

• Operating Performance: Operating revenues increased 20% to $1.22 million, driven by expanded sales of the BVA-100 analyzer and related kits. However, operating expenses rose significantly to $4.70 million (from $4.16 million), resulting in an operating loss of $3.48 million.
• Investment Income: Dividend income increased to $1.99 million, and gains on the sale of investments surged to $989,599 (compared to $238,550 in 2003). These investment returns were critical in reducing the net loss from $1.08 million to $0.58 million.
• Debt Levels: Short-term debt increased to $4.11 million (from $2.50 million), consisting of bank loans and margin debt secured by the company's securities portfolio.
• Asset Growth: Total assets grew by approximately $7.6 million, primarily due to the appreciation of the available-for-sale securities portfolio.

Outlook, Risks, and Management Commentary

Strategy: Management intends to focus major marketing efforts on the Blood Volume Analyzer, anticipating it will become the primary revenue source. The company is expanding its sales staff and utilizing leasing arrangements (via De Lage Landen) to reduce capital outlay for equipment.

Risks and Contingencies:

• Operational Dependence: The company relies heavily on investment income to offset operating losses. Continued losses from operations are expected as marketing expenses increase.
• Market Acceptance: Success depends on demonstrating the cost-effectiveness and accuracy of blood volume measurement to the medical community.
• Regulatory: Products are subject to FDA regulation. The company has received clearance for the BVA-100 and Volumex kit.
• Legal: A lawsuit filed in 2004 was dismissed in 2005. A subsequent event in February 2005 involved a settlement with a landlord for approximately $45,000 in additional rent, which was accrued at year-end.
• Accounting Changes: The company is preparing to adopt FAS 123R (Share-Based Payment) in Q3 2005, which will require expensing the fair value of stock options, potentially impacting future net income.

Investor Verification Checklist

• Investment Portfolio Reliance: Verify the stability of the utility stock portfolio, which generated nearly $3 million in income (dividends + gains) to cover operating losses.
• Operating Cash Burn: Confirm the sustainability of the $1.83 million cash burn from operations given the current cash balance of only $5,079.
• Debt Covenants: Review the terms of the $4.1 million in short-term debt, which is secured by the company's marketable securities.
• Revenue Recognition: Examine the mix of direct sales, leases, and rental income for the BVA-100 to understand the quality and recurring nature of operating revenue.
• Stock Option Impact: Assess the potential impact of the upcoming FAS 123R adoption on future earnings per share.